Du är här

2014-04-29

MorphoSys AG: MorphoSys and Temple University Sign Therapeutic Antibody Discovery Partnership

MorphoSys AG / MorphoSys and Temple University Sign Therapeutic Antibody
Discovery Partnership. Processed and transmitted by NASDAQ OMX Corporate
Solutions. The issuer is solely responsible for the content of this
announcement.
Alliance is Based on MorphoSys's Next-Generation Ylanthia Technology

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and The
Moulder Center for Drug Discovery Research, a unit of Temple University's
School of Pharmacy, Philadelphia, Pa., USA, today announced a strategic
alliance focused on the discovery of new therapeutic antibodies. Under the
terms of the agreement, the Moulder Center will receive access to MorphoSys's
Ylanthia® technology for use in validating new disease-related targets and
generating therapeutic antibody candidates. MorphoSys will receive an
exclusive option to develop any resulting antibodies. Financial details of
the agreement were not disclosed.

The Ylanthia library will be installed at Temple's Moulder Center for Drug
Discovery Research, a multidisciplinary research hub for the further
development of scientific discoveries identified by Temple University faculty
and scientists, as well as its external academic and industrial partners,
into novel therapies. Its Biotherapeutics Discovery Unit under the leadership
of Dr. Jon Condra is dedicated to working on drug design and lead
optimization in multiple disease areas, including cancer, Alzheimer's
disease, cardiovascular, metabolic and viral diseases.

"We are very much looking forward to cooperating with MorphoSys. Having
already worked with their technologies in my former position in Merck's
Department of Biologics Research, I know about the excellent quality of
MorphoSys's antibody libraries and the company's development capabilities,"
said Dr. Condra, Associate Professor of Pharmaceutical Biotechnology at
Temple and a member of the Moulder Center. "The highly specific and fully
human antibodies we will be able to generate with Ylanthia will form the
ideal basis to discover new therapeutic agents. Collaborations with a strong
industrial partner like MorphoSys contribute substantially to the scientific
advancement of drug discovery and development."

"In enhancing our facilities and capabilities at the Moulder Center for Drug
Discovery Research, we are focused on efficiently generating research data
using a host of technologies and tools," said Dr. Magid Abou-Gharbia,
Associate Dean for Research in Temple's School of Pharmacy and Director of
the Moulder Center. "Our new collaborative effort with MorphoSys will provide
our faculty, staff, and students with the cutting-edge scientific tools
necessary to identify the next generation of antibody therapeutics."

"The collaboration with Temple embeds our latest technology, Ylanthia, in the
scientific community and has the potential to expand our pipeline of exciting
new drug candidates in the long term", commented Dr. Marlies Sproll, Chief
Scientific Officer of MorphoSys AG. "Access to novel disease-related target
molecules is a key asset for any biopharmaceutical company and this alliance
leverages our Ylanthia technology to source potentially interesting antibody
leads for therapeutic applications."

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 80 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and
Ylanthia® and 100 billion high potentials® are registered trademarks of
MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

About The Moulder Center:
The Moulder Center for Drug Discovery Research was established in 2008 as a
multidisciplinary drug discovery research hub in the Temple University School
of Pharmacy. Equipped with unique capabilities and experienced scientists,
the Center is actively pursuing collaborative research opportunities within
Temple University and with external collaborators in the academic community,
as well as industrial partners both in the U.S. and abroad. Moulder
researchers are dedicated to facilitating these collaborative research
efforts to support the discovery and development of novel therapeutic agents
to improve the health and life of patients. The Center is led by its founding
director, Dr. Magid Abou-Gharbi, who has over 26 years of pharmaceutical
industry experience as Senior Vice President of Discovery Research at Wyeth
Pharmaceutical. On the web athttp://moulder.temple.edu/.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR,
Mario Brkulj
Associate Director Corporate Communications&IR,
Alexandra Goller
Specialist Corporate Communications&IR,
Jessica Rush
Specialist Corporate Communications&IR,
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Temple University
Preston M. Moretz
Office of Strategic Marketing&Communications
pmoretz@temple.edu

Tel: +1-215-204-4380

Media Release (PDF)
http://hugin.info/130295/R/1780490/608758.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1780490

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.